JP2003500360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003500360A5 JP2003500360A5 JP2000619438A JP2000619438A JP2003500360A5 JP 2003500360 A5 JP2003500360 A5 JP 2003500360A5 JP 2000619438 A JP2000619438 A JP 2000619438A JP 2000619438 A JP2000619438 A JP 2000619438A JP 2003500360 A5 JP2003500360 A5 JP 2003500360A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- group
- fap
- post
- reactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 108010050095 PT-100 dipeptide Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- FKCMADOPPWWGNZ-YUMQZZPRSA-N [(2r)-1-[(2s)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O FKCMADOPPWWGNZ-YUMQZZPRSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13586199P | 1999-05-25 | 1999-05-25 | |
| US60/135,861 | 1999-05-25 | ||
| PCT/US2000/014505 WO2000071135A1 (en) | 1999-05-25 | 2000-05-25 | Anti-tumor comprising boroproline compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003500360A JP2003500360A (ja) | 2003-01-07 |
| JP2003500360A5 true JP2003500360A5 (enExample) | 2007-07-19 |
Family
ID=22470056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000619438A Pending JP2003500360A (ja) | 1999-05-25 | 2000-05-25 | ボロプロリン化合物類を含む抗癌剤 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1187619A1 (enExample) |
| JP (1) | JP2003500360A (enExample) |
| AU (1) | AU781897B2 (enExample) |
| CA (1) | CA2373643A1 (enExample) |
| HK (1) | HK1046846A1 (enExample) |
| WO (1) | WO2000071135A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001518290A (ja) | 1997-09-29 | 2001-10-16 | ポイント セラピューティクス， インコーポレイテッド | インビトロでの造血細胞の刺激 |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| BR0114604A (pt) | 2000-10-12 | 2003-10-14 | Pharma Mar Sa | Tratamento de cnceres |
| WO2003037373A1 (en) * | 2001-10-31 | 2003-05-08 | Medical Research Council | Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer |
| JP4771661B2 (ja) * | 2001-11-26 | 2011-09-14 | トラスティーズ オブ タフツ カレッジ | Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤 |
| JP2003267966A (ja) * | 2002-03-13 | 2003-09-25 | Pola Chem Ind Inc | フラバン誘導体、皮膚線維芽細胞増殖抑制剤および皮膚外用剤 |
| WO2004004661A2 (en) * | 2002-07-09 | 2004-01-15 | Point Therapeutics, Inc. | Boroproline compound combination therapy |
| JP4584245B2 (ja) | 2003-03-12 | 2010-11-17 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 多発性骨髄腫治療用のアプリジン |
| WO2004080293A2 (en) * | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Methods for diagnosing skin lesions |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| WO2009148623A2 (en) | 2008-06-05 | 2009-12-10 | Stc.Unm | Methods and related compositions for the treatment of cancer |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| JP2013523819A (ja) | 2010-04-06 | 2013-06-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9284337B2 (en) * | 2011-11-22 | 2016-03-15 | Trustees Of Tufts College | Small molecule enhancer for dendritic cell cancer vaccines |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| CN107683135A (zh) | 2015-03-09 | 2018-02-09 | 因特克林医疗有限公司 | 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
| WO2018056907A1 (en) * | 2016-09-21 | 2018-03-29 | Agency For Science, Technology And Research | Methods and compositions for inhibiting skin inflammation and determining cancer susceptibility |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| TWI812820B (zh) * | 2018-12-10 | 2023-08-21 | 美商百歐克斯賽爾治療公司 | 使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法 |
| CN115779148B (zh) * | 2021-09-09 | 2024-02-23 | 中国科学院福建物质结构研究所 | 一种牙种植体表面涂层及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02268118A (ja) * | 1989-04-07 | 1990-11-01 | Mitsubishi Gas Chem Co Inc | 免疫賦活剤 |
| US5328936A (en) * | 1993-02-01 | 1994-07-12 | Rohm And Haas Company | Polymerization process for making porous polymeric particles |
| IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5767242A (en) * | 1994-04-20 | 1998-06-16 | Boehringer Ingelheim Int'l Gmbh | Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| US5952301A (en) * | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
| US6100234A (en) * | 1997-05-07 | 2000-08-08 | Tufts University | Treatment of HIV |
| AU765370B2 (en) * | 1998-06-05 | 2003-09-18 | Point Therapeutics, Inc. | Cyclic boroproline compounds |
| CA2339537A1 (en) * | 1998-08-21 | 2000-03-02 | Barbara Wallner | Regulation of substrate activity |
-
2000
- 2000-05-25 HK HK02106843.4A patent/HK1046846A1/zh unknown
- 2000-05-25 CA CA002373643A patent/CA2373643A1/en not_active Abandoned
- 2000-05-25 WO PCT/US2000/014505 patent/WO2000071135A1/en not_active Ceased
- 2000-05-25 JP JP2000619438A patent/JP2003500360A/ja active Pending
- 2000-05-25 EP EP00937801A patent/EP1187619A1/en not_active Withdrawn
- 2000-05-25 AU AU52927/00A patent/AU781897B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7579365B2 (en) | Indolyl-3-glyoxylic acid derivatives having antitumor action | |
| JP5046922B2 (ja) | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 | |
| WO2001024763A3 (en) | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents | |
| CA2560058A1 (en) | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis | |
| MY124390A (en) | Substituted bicyclic derivatives useful as anticancer agents | |
| BG106003A (en) | New n-cyanomethylamides and compositions as protease inhibitors | |
| AU2003225617A1 (en) | Thiadiazolylpiperazine derivatives useful for treating or preventing pain | |
| DE69928567D1 (de) | Biodegradierbare polyphosphoester-zusammensetzungen zur behandlung von ovarialkrebs | |
| WO2003013541A8 (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | |
| MXPA03007837A (es) | Composiciones para suministrar bisfosfonatos. | |
| AU2001296865A1 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
| AU4431200A (en) | 4'-c-ethynyl pyrimidine nucleosides | |
| HK1046846A1 (zh) | 包含boroproline的抗肿瘤复合物 | |
| AU3492100A (en) | Oxadiazole compounds and compositions for delivering active agents | |
| AU3850600A (en) | Dalda analogs and their use | |
| CA2350815A1 (en) | Stable amorphous amifostine compositions and methods for the preparation and use of same | |
| IL167990A (en) | Cytarabine monophosphate analog, pharmaceutical compositions comprising it and use thereof in the manufacture of medicaments | |
| MXPA02001571A (es) | Metodo de tratamiento para el cancer. | |
| UA83738C2 (en) | [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | |
| NZ514558A (en) | Viral treatment | |
| UA81640C2 (ru) | Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе | |
| Rahier et al. | Water-soluble camptothecin derivatives that are intrinsic topoisomerase I poisons | |
| JP3094036B2 (ja) | 酵素不活性化剤 | |
| FR2699176B1 (fr) | Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant. | |
| Liu et al. | A study on the levels of calmodulin and DNA in human lung cancer cells |